Loading organizations...
We Venture Capital is the corporate venture arm of Werfen, a leader in diagnostics. It invests globally in early-stage startups and early-scale-ups within the diagnostics sector, focusing on digital solutions and life science tools. The firm blends venture capital agility with Werfen's industry understanding, providing strategic insights, global reach, and expertise to its portfolio.
Established by Werfen, the firm originated from the insight that a diagnostics leader could identify and nurture disruptive technologies. Leveraging Werfen’s extensive experience and market position, We Venture Capital fosters innovation within its core areas. This initiative demonstrates a commitment to shaping diagnostics' future through direct investment and partnership.
The firm collaborates with promising diagnostics startups, empowering them with Werfen’s knowledge and tailored support. We Venture Capital actively engages with its portfolio companies, often through board representation, utilizing its strategic mindset and professional network. Its vision focuses on forging lasting collaborations, dedicated to ensuring successful outcomes and advancing the diagnostics industry.
We Venture Capital has 3 tracked investments across 3 companies. The latest tracked deal is $57.0M Series C in DeepUll in April 2025.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Apr 1, 2025 | DeepUll | $57.0M Series C | Columbus Venture Partners, Merieux Equity Partners, Panakes Partners | Asabys Partners, Vsquared Ventures, Aliath Bioventures, Axis Participaciones Empresariales, CDTI Innvierte, Kurma Partners, UI Investissement |
| Apr 18, 2024 | Cognivia | $16.5M Other Equity | — | Sfpi Fpim, Vesalius Biocapital IV |
| Oct 24, 2023 | Sendy | $5.2M Series B Extension | WE Venture Capital | — |